这是一篇来自已证抗体库的有关人类 CYP1A2的综述,是根据10篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合CYP1A2 抗体。
CYP1A2 同义词: CP12; CYPIA2; P3-450; P450(PA)

圣克鲁斯生物技术
小鼠 单克隆(d15)
  • 免疫组化-石蜡切片; 小鼠; 1:100; 图 2a
  • 免疫印迹; 小鼠; 1:1000; 图 2b
圣克鲁斯生物技术 CYP1A2抗体(Santa Cruz, sc-53241)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:100 (图 2a) 和 被用于免疫印迹在小鼠样本上浓度为1:1000 (图 2b). Cell Rep Med (2022) ncbi
小鼠 单克隆(d15)
  • 免疫组化-石蜡切片; 人类; 1:200; 图 8g
  • 免疫细胞化学; 人类; 1:200; 图 6s1d
圣克鲁斯生物技术 CYP1A2抗体(Santa Cruz, sc-53241)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:200 (图 8g) 和 被用于免疫细胞化学在人类样本上浓度为1:200 (图 6s1d). elife (2019) ncbi
小鼠 单克隆
  • 免疫印迹; 人类; 1:500; 图 6h
圣克鲁斯生物技术 CYP1A2抗体(SantaCruz, sc-393783)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 6h). Biochem Pharmacol (2017) ncbi
小鼠 单克隆(d15)
  • 免疫印迹; 小鼠; 1:1000; 图 10a
圣克鲁斯生物技术 CYP1A2抗体(SantaCruz, sc-53241)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 10a). Drug Metab Dispos (2017) ncbi
小鼠 单克隆(3B8C1)
  • 免疫印迹; 人类; 图 6b
圣克鲁斯生物技术 CYP1A2抗体(Santa Cruz, sc-53614)被用于被用于免疫印迹在人类样本上 (图 6b). Toxicol Lett (2016) ncbi
小鼠 单克隆(d15)
  • 免疫印迹; 人类; 图 2
圣克鲁斯生物技术 CYP1A2抗体(Santa Cruz, SC-53241)被用于被用于免疫印迹在人类样本上 (图 2). PLoS ONE (2016) ncbi
小鼠 单克隆(3B8C1)
  • 免疫印迹; 人类
圣克鲁斯生物技术 CYP1A2抗体(Santa Cruz Biotechnology, sc-53614)被用于被用于免疫印迹在人类样本上. Biotechnol Bioeng (2013) ncbi
艾博抗(上海)贸易有限公司
小鼠 单克隆(3B8C1)
  • 免疫组化; 人类; 1:1000; 图 4a
艾博抗(上海)贸易有限公司 CYP1A2抗体(Abcam, 3B8C1)被用于被用于免疫组化在人类样本上浓度为1:1000 (图 4a). Sci Rep (2022) ncbi
domestic rabbit 单克隆(EPR6138(2))
  • 免疫组化; common marmoset; 图 6
艾博抗(上海)贸易有限公司 CYP1A2抗体(Abcam, ab151728)被用于被用于免疫组化在common marmoset样本上 (图 6). Hepat Med (2020) ncbi
赛默飞世尔
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 1d
赛默飞世尔 CYP1A2抗体(ThermoFisher, PA1-341)被用于被用于免疫印迹在人类样本上 (图 1d). Toxicol In Vitro (2017) ncbi
文章列表
  1. Hu S, Liu S, Bian Y, Poddar M, Singh S, Cao C, et al. Single-cell spatial transcriptomics reveals a dynamic control of metabolic zonation and liver regeneration by endothelial cell Wnt2 and Wnt9b. Cell Rep Med. 2022;3:100754 pubmed 出版商
  2. Uehara S, Iida Y, Ida Tanaka M, Goto M, Kawai K, Yamamoto M, et al. Humanized liver TK-NOG mice with functional deletion of hepatic murine cytochrome P450s as a model for studying human drug metabolism. Sci Rep. 2022;12:14907 pubmed 出版商
  3. Aravalli R, COLLINS D, Hapke J, Crane A, Steer C. Hepatic Differentiation of Marmoset Embryonic Stem Cells and Functional Characterization of ESC-Derived Hepatocyte-Like Cells. Hepat Med. 2020;12:15-27 pubmed 出版商
  4. Katsuda T, Matsuzaki J, Yamaguchi T, Yamada Y, Prieto Vila M, Hosaka K, et al. Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes. elife. 2019;8: pubmed 出版商
  5. Chen Y, Zeng L, Wang Y, Tolleson W, Knox B, Chen S, et al. The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. Biochem Pharmacol. 2017;145:178-191 pubmed 出版商
  6. Cheng S, Bammler T, Cui J. RNA Sequencing Reveals Age and Species Differences of Constitutive Androstane Receptor-Targeted Drug-Processing Genes in the Liver. Drug Metab Dispos. 2017;45:867-882 pubmed 出版商
  7. Vogel K, Ainslie G, Roullet J, McConnell A, Gibson K. In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of ?-hydroxybutyrate (GHB) binding. Toxicol In Vitro. 2017;40:196-202 pubmed 出版商
  8. Štěpánková M, Krasulová K, Doricakova A, Kurka O, Anzenbacher P, Dvorak Z. Optical isomers of dihydropyridine calcium channel blockers display enantiospecific effects on the expression and enzyme activities of human xenobiotics-metabolizing cytochromes P450. Toxicol Lett. 2016;262:173-186 pubmed 出版商
  9. Rasmussen M, Balaguer P, Ekstrand B, Daujat Chavanieu M, Gerbal Chaloin S. Skatole (3-Methylindole) Is a Partial Aryl Hydrocarbon Receptor Agonist and Induces CYP1A1/2 and CYP1B1 Expression in Primary Human Hepatocytes. PLoS ONE. 2016;11:e0154629 pubmed 出版商
  10. Yang Y, Li J, Pan X, Zhou P, Yu X, Cao H, et al. Co-culture with mesenchymal stem cells enhances metabolic functions of liver cells in bioartificial liver system. Biotechnol Bioeng. 2013;110:958-68 pubmed 出版商